Cyclic nonapeptide with repairing and anti-oxidation effects and application of cyclic nonapeptide
By designing the amino acid sequence of the cyclic nonapeptide as a ring (arginine-glycine-aspartic acid-serine-arginine-lysine-valine-lysine-serine), it combines with integrin to inhibit the MAPK pathway and trigger TGF-β release, thus solving the problem of the lack of both repair and antioxidant effects in the existing technology, and achieving significant antioxidant and repair effects.
Patent Information
- Application Number
- CN202511659703.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2025-11-13
- Publication Date
- 2026-01-16
AI Technical Summary
There is no existing literature documenting that RGDS and KVK are linked by amino acids to form a cyclic nonapeptide structure, thus failing to possess both repair and antioxidant effects.
A cyclic nonapeptide with a cyclic amino acid sequence (arginine-glycine-aspartic acid-serine-arginine-lysine-valine-lysine-serine) was designed to inhibit the MAPK pathway, reduce lipopolysaccharide-induced inflammation, and decrease ROS production by binding to integrin αVβ3 and α5β1. Furthermore, it can trigger TGF-β release by mimicking the function of TSP-1 through KVK peptide, thereby promoting keratinocyte proliferation and migration.
Cyclononapeptide significantly inhibited ROS production in HaCaT cells at concentrations of 70 μg/mL and 140 μg/mL, promoted cell healing, and achieved antioxidant and repair effects, while exhibiting good solubility and structural stability.